IMR Press / EJGO / Volume 23 / Issue 4 / pii/2002163

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Impact of maintenance chemotherapy on disease-free survival in patients with stage le and II epithelial ovarian cancer

Show Less
1 Department of Reproductive Medicine, Chiba University Graduate School of Medicine, Chiba (Japan)
2 Department of Molecular Pathology, Chiba University Graduate School of Medicine, Chiba (Japan)
3 Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba (Japan)
Eur. J. Gynaecol. Oncol. 2002, 23(4), 281–286;
Published: 10 August 2002
Abstract

Purpose of investigation: To evaluate the impact on disease free survival (DFS) with maintenance chemotherapy following com­plete surgery and adjuvant chemotherapy in patients with stage Ic and II epithelial ovarian cancer by a retrospective study. Methods: One hundred and forty patients with stage le and stage II epithelial ovarian cancer were classified into three groups according to the modality of maintenance chemotherapy (no therapy, oral or intravenous administration of anti-cancer drugs). DFS was compared among the three groups, and independent predictive factors for relapse were analyzed. Results: There were no statistically significant differences in DFS among the three groups for either stage Ic or II cancers, stage Ic and stage II. Multivariate analysis revealed that independent predictive factors for relapse were stage II (p = 0.004) in all patients and less than three cycles of adjuvant chemotherapy in stage II patients (p = 0.015). Conclusion: Maintenance chemotherapy had no impact on DFS in patients with stage Ic or II epithelial ovarian cancer.

Keywords
Epithelial ovarian cancer
Maintenance chemotherapy
Disease-free survival
Share
Back to top